肝功能或肾功能不全对Aficamten药代动力学的影响
本研究评估了Aficamten在中度肝功能损害或轻至中度肾功能损害患者中的药代动力学。一项1期开放标签平行组研究比较了中度肝功能损害(Child-Pugh B,n=8)与肝功能正常者(n=8)单次口服20mg Aficamten的药代动力学,肾功能损害的影响则通过群体药代动力学模型分析2/3期临床数据。结果显示中度肝功能损害和轻至中度肾功能损害均未引起Aficamten药代动力学的临床相关改变,可能无需调整剂量。
要点
- 中度肝功能损害(Child-Pugh B)患者单次20mg Aficamten的药代动力学与肝功能正常者相似。
- 轻至中度肾功能损害对oHCM患者的Aficamten暴露无临床意义的影响。
- 轻至中度肝功能或肾功能损害患者可能无需调整Aficamten剂量。
核心结论
- 中度肝功能损害未引起Aficamten药代动力学的临床相关改变。
- 轻至中度肾功能损害对oHCM患者的Aficamten药代动力学无统计学或临床显著影响。
研究设计与样本
- 1期单次给药、开放标签、平行组研究:中度肝功能损害(Child-Pugh B,n=8)与肝功能正常者(n=8)比较,单次口服Aficamten 20mg。
- 肾功能损害影响通过2/3期临床数据的群体药代动力学模型评估。
主要发现
- 中度肝功能损害者与肝功能正常者的Aficamten药代动力学相似。
- 未报告严重或重度治疗中出现的不良事件或临床显著实验室异常。
- 轻至中度肾功能损害的oHCM患者与肾功能正常者的Aficamten暴露无临床意义差异。
临床怎么用
- 轻至中度肝功能或肾功能损害的oHCM患者可能无需调整Aficamten剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Aficamten, a small-molecule, selective cardiac myosin inhibitor, is under development for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Aficamten is primarily eliminated by hepatic metabolism with renal excretion playing a minor role. The objective of this investigation was to evaluate the pharmacokinetics (PK) of aficamten in moderate hepatic impairment or mild to moderate renal impairment to inform dosing recommendations in HCM patients with mild or moderate hepatic impairment or mild to moderate renal impairment. METHODS: The impact of hepatic impairment on the PK of single-dose aficamten 20 mg was evaluated in a phase 1 single-dose, open-label, parallel-group study, in healthy participants with moderate (n = 8) hepatic impairment (Child-Pugh B classification) versus participants with normal hepatic function (n = 8). Safety was monitored throughout. The effect of renal impairment on aficamten PK was assessed using population PK (PopPK) modelling of phase 2/3 clinical data in patients with oHCM. RESULTS: Aficamten PK was similar in participants with moderate hepatic impairment and those with normal hepatic function. No serious or severe treatment-emergent adverse events or clinically significant laboratory abnormalities were reported. There were no clinical meaningful differences in aficamten exposure in patients with oHCM with mild or moderate renal impairment and those with normal renal function. CONCLUSIONS: No clinically relevant changes in aficamten PK were observed in participants with moderate hepatic impairment. Population PK analysis indicated mild or moderate renal impairment and had no statistically or clinically significant impact on aficamten PK in patients with oHCM. Aficamten dose adjustment may not be necessary in patients with mild or moderate hepatic or renal impairment.
引用
- Xu D, Lutz JD, Divanji P, et al. Effect of Hepatic Impairment or Renal Impairment on the Pharmacokinetics of Aficamten. Clin Pharmacokinet. 2025. PMID: 39907965. doi:10.1007/s40262-025-01481-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。